Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tenapanor - Ardelyx

Next Previous
Drug Profile

Tenapanor - Ardelyx

Alternative Names: AZD-1722; AZD1722-hydrochloride; IBSRELA; Ibsrela; KHK-7791; PHOZEVEL; RDX-5791; Tenapanor hydrochloride; Wan Ti Le; XPHOZAH

Latest Information Update: 28 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ardelyx
  • Developer Ardelyx; Knight Therapeutics; Kyowa Kirin; Shanghai Fosun Pharmaceutical
  • Class Benzylisoquinolines; Chlorinated hydrocarbons; Ethers; Gastrokinetics; Heart failure therapies; Hyperphosphataemia therapies; Irritable bowel syndrome therapies; Small molecules; Sulfonamides; Urea compounds; Urologics
  • Mechanism of Action Sodium-hydrogen exchanger 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperphosphataemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperphosphataemia; Irritable bowel syndrome
  • Phase III Constipation
  • Phase II Renal failure
  • Discontinued Heart failure

Most Recent Events

  • 28 Aug 2026 No recent reports of development identified for phase-I development in Irritable-bowel-syndrome in China (PO)
  • 07 Jul 2026 Ardelyx completes phase-II clinical trials in Irritable bowel syndrome (In children) in USA (PO) (NCT06553547)
  • 23 Apr 2026 Pharmacodynamics data from a preclinical studies in Irritable bowel syndrome released by Ardelyx

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top